Canigen Bb, an inactivated subunit vaccine, provides active immunisation against Bordetella bronchiseptica in dogs. It reduces the clinical signs of upper respiratory tract disease while also reducing bacterial shedding post-infection.
Administered via subcutaneous injection, Canigen Bb offers clinicians a new tool in the fight against kennel cough in dogs where intra-nasal Bordetella bronchiseptica vaccination is not possible or preferred.
Licensed for use in dogs from six weeks of age, Canigen Bb extends protection against Bordetella bronchiseptica in dogs vaccinated with Canigen KC in the last 12 months for a further year with a single dose.
Canine infectious respiratory disease (CIRD), otherwise known as kennel cough or infectious tracheobronchitis, is widely recognised as one of the most common infectious diseases in dogs (Buonavoglia and Martella, 2007). Bordetella bronchiseptica is a clinically significant pathogen for the disease with 78.7 percent of dogs with acute respiratory signs testing positive for the bacteria (Scultz et al., 2014). Forty-five-point-six percent of clinically healthy dogs also tested positive for Bordetella bronchiseptica, illustrating that clinically healthy dogs can carry respiratory pathogens and could act as sources of infection for susceptible dogs (Scultz et al., 2014).
“Canigen Bb offers clinicians an ideal solution to provide protection against Bordetella bronchiseptica in dogs where, for whatever reason, administering an intra-nasal vaccine is difficult or in pets who are in contact with known immunocompromised individuals where a live aerosolised vaccine may be less appropriate,” said Andrew Connolly, marketing director (UK and Ireland) at Virbac. “It is our hope that Canigen Bb will increase the overall uptake of Bordetella bronchiseptica vaccination to provide increased protection against this widely prevalent and clinically significant disease.”
Canigen Bb is conveniently presented as a ready to use formula in a 10ml multi-dose bottle and can be stored at room temperature (2 to 25°C) for up to four weeks once broached. It can be administered concurrently (at the same time but separate injections) with Canigen DHP, Canigen DHPPi, Canigen Pi and Canigen Lepto 4.
To find out more about Canigen Bb, or to learn how Virbac’s vaccine support could benefit you and your practice, please speak to your local Virbac Territory Manager.
